Pravastatin Prevents Aortic Atherosclerosis via Modulation of Signal Transduction and Activation of Transcription 3 (STAT3) to Attenuate Interleukin-6 (IL-6) Action in ApoE Knockout Mice by Zhou, Xiaoxu et al.
Int. J. Mol. Sci. 2008, 9, 2253-2264; DOI: 10.3390/ijms9112253  
 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
www.mdpi.com/journal/ijms/ 
Article 
 
Pravastatin Prevents Aortic Atherosclerosis via Modulation of 
Signal Transduction and Activation of Transcription 3 (STAT3) 
to Attenuate Interleukin-6 (IL-6) Action in ApoE Knockout 
Mice 
 
Xiaoxu Zhou 
1,#, Dan Li 
2,#, Wei Yan 
1 and Weimin Li 
1,* 
 
1  Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, 23 
Youzheng Str, Nangang District, Harbin 150001, P.R. China. E-Mails: zhouxiaoxu@yahoo.com.cn 
(X. Z.); yanwei7777@yahoo.com.cn (W. Y.) 
2  Eye hospital, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Str, 
Nangang District, Harbin 150001, P.R. China. E-Mail: ld_anny@hotmail.com (D. L.) 
 
*  Author to whom correspondence should be addressed; E-Mail: dr_liweimin@yahoo.com.cn;  
Tel. +86-13804601998; Fax: +86-0451-86890380 
 
#  These authors contributed equally to this work 
 
Received: 27 September 2008; in revised form: 4 November 2008 / Accepted: 7 November 2008 / 
Published: 14 November 2008 
 
 
Abstract: The purpose of this study was to determine whether pravastatin’s prevention 
of aortic atherosclerosis via attenuation of IL-6 action depends on modulation of STAT3 
activity. Male apoE knockout (apoE-/-) mice fed on a diet containing 1.25% cholesterol 
(wt/wt) were divided into pravastatin group provided with pravastatin (80 mg kg
-1 per 
day) and atherosclerosis group. After eight weeks, pravastatin significantly prevented 
atherosclerotic lesion and reduced levels of IL-6 in serum and lesion, and significantly 
decreased expressions of phosphorylated STAT3 (pSTAT3) and increased suppressor of 
cytokine signaling 3 (SOCS3) expressions in lesions. Our results suggested that 
pravastatin’s aortic atherosclerosis preventing action via attenuation of IL-6 action may 
partially depend on modulation of STAT3 activity. 
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1. Introduction 
Atherosclerosis is the underlying disorder in the majority of patients with cardiovascular disease 
and is commonly considered to be an inflammatory vascular disease [1]. Recent research has 
established a key pathogenic role for several inflammatory mediators, such as IL-6, in all stages of this 
disease [2, 3]. Activation of IL-6 signal transduction involves gp130 dimerization [4], followed by 
tyrosine phosphorylation of STAT3. STAT3 is the primary mediator of the IL-6-Janus kinase (JAK)-
STAT3 signaling pathway and is responsible for the nuclear actions of IL-6 [5]. The SOCS proteins 
are a growing family of suppressors of cytokine signaling molecules that are feedback inhibitors of 
cytokine signaling pathways [6]. The signaling of IL-6 can be inhibited by SOCS3 [7]. 
The local JAK-STAT3 pathway is important in controlling diverse pathways in the cardiovascular 
system [8, 9] and IL-6-JAK-STAT3 pathway could be activated in atherosclerosis [10]. To summarize, 
not only STAT intracellular signaling pathways can be associated with atherosclerosis, but STAT 
proteins also help explain new properties of therapeutic agents [11]. Therefore, a therapeutic strategy 
targeting STAT3 activity may be beneficial in treating atherosclerosis.  
Pravastatin, a hydrophilic inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA), has 
lipid-lowering activity and influences on main mechanisms of atherogenesis [12]. Pravastatin has a 
direct positive effect on plaque stability that is unrelated to lipid lowering. Improvements in plaque 
stability must have resulted from some other actions of pravastatin, an effect usually described as 
pleiotropism [13]. Recent works pointed to beneficial pleiotropic (nonlipid) effects of pravastatin 
include anti-inflammatory action [14, 15] and additional cholesterol-independent effects of statins on 
cellular signal transductions [16]. However, the relationship between pravastatin preventing aortic 
atherosclerosis and modulating STAT3 remains elusive.  
To elucidate the cellular and molecular mechanisms involved in pravastatin prevention of 
atherosclerosis, we investigated the impact of pravastatin on STAT3 activity in combating 
atherosclerosis in apoE-/- mice.  
 
2. Results and Discussion  
 
2.1. Analysis of atherosclerotic lesions 
 
We determined the size of the atherosclerotic lesion in each group of the mice. In the present 
experiment, the mice in the atherosclerotic group showed atherosclerosis lesions in the aortic root, 
while the mice in the pravastatin group showed a marked reduction in aortic lesion size. (Figure 1A). 
Quantitative analysis of atherosclerotic area was expressed by the ratio of the lesion area versus the 
total vessel wall area. As shown in Figure 1B, the ratio in atherosclerotic mice (33.20%) was increased 
compared with that in control mice (5.32%) (P <0.01), on the other hand, the ratio in mice provided 
with pravastatin (9.65%) was lessened, compared with that in the atherosclerotic mice (P <0.05). Int. J. Mol. Sci. 2008, 9  
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Figure 1. A. Representative photomicrographs show paraffin sections of atherosclerotic 
plaques from aortic roots of mice. Magnification 100X for Hematoxylin and Eosin staining.  
B. Ratio of the atherosclerotic lesion area compared to the total vessel wall area in mice. 
## 
Р＜0.01 versus control mice; * P＜0.05 versus atherosclerosis mice. (n=6 per group). 
 
 
 
 
2.2. Analysis of serum lipid 
 
As shown in Table 1, the serum levels of low density lipoprotein-cholesterol (LDL-C) (21.76±6.29 
mmol L
-1) and total cholesterol (TC) (26.59±7.25 mmol L
-1) in atherosclerotic mice were significantly 
increased compared with that of LDL-C (0.27±0.12 mmol L
-1) and TC (2.23±0.60 mmol L
-1) in control 
mice (P < 0.01), however those concentrations of LDL-C (12.81±9.14 mmol L
-1) and TC (17.20±11.67 
mmol L
-1) were not significantly different in mice provided with pravastatin, in contrast to 
atherosclerotic mice. 
 
Table 1. Concentrations of LDL-C and TC in mice serum. 
Groups  Serum LDL-C (mmol L
-1)  Serum TC (mmol L
-1) 
Control 0.27±0.12  2.23±0.60 
Atherosclerosis 21.76±6.29 
## 26.59±7.25
 ## 
Pravastatin 12.81±9.14  17.20±11.67 
Data are represented as means±SD (n=6). 
##  ＜ Р 0.01 compared with control mice.   
(n=6 per group) 
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2.3. Concentrations of IL-6 in serum and aorta 
 
Concentrations of IL-6 in serum and aorta were measured by ELISA. As is shown in Figures 2 and 
3, concentrations of IL-6 in serum (17.99±2.51 pg mL
-1) and aorta (176.04±77.62 pg mg
-1 protein) of 
atherosclerotic mice were significantly increased compared with concentrations of IL-6 in serum 
(9.93±6.57 pg mL
-1) and aorta (40.56±14.79 pg mg
-1 protein) of control mice (P <0.01), but   
concentrations of IL-6 in serum (10.56±2.56 pg mL
-1) and aorta (45.49±15.01 pg mg
-1 protein) of mice 
provided with pravastatin were significantly decreased compared with IL-6 concentrations in serum 
and aorta of atherosclerotic mice (P <0.01) 
 
Figure 2. Concentrations of IL-6 (pg mL
-1) in serum were measured by ELISA. 
##Р＜0.01 
versus control mice; ** P＜0.01 versus atherosclerosis mice (n=6 per group). 
 
Figure 3. Concentrations of IL-6 (pg mg
-1 protein) in thoracoabdominal aorta are 
measured by ELISA. 
##Р＜0.01 versus control mice; ** P＜0.01 versus atherosclerosis 
mice (n=6 per group). 
 
 
2.4. Expression of pSTAT3 in aorta 
 
It is well known that pSTAT3 acts on the active form of STAT3. The expression of pSTAT3 in 
thoracoabdominal aorta was examined by Western Blotting. As shown in Figure 4, the expression of 
pSTAT3 in atherosclerotic mice was significantly up-regulated compared with that observed in control 
mice, while that expression in mice provided with pravastatin were significantly down-regulated 
compared with that in atherosclerotic mice. Three similar experiments had similar results.  
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Figure 4. A. Expressions of pSTAT3 and STAT3 proteins extracted from the 
thoracoabdominal aortas of mice and examined by Western Blotting. B. The expression of 
pSTAT3 protein was quantified by MutiGauge V 3.0 Imager and normalized to STAT3 
protein (n=6 per group). 
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2.5. Expressions of SOCS3 in aorta  
 
SOCS3 can regulate STAT3 activity in a negative way. The expression of SOCS3 in 
thoracoabdominal aorta was examined by Western Blotting. As shown in Figure 5, the expression of 
SOCS3 in atherosclerotic mice were significantly attenuated compared with that seen in control mice, 
while simultaneously, that expression in mice provided with pravastatin was significantly heightened 
compared with that in atherosclerotic mice. Three similar experiments had similar results. 
In the present study, the aortic atherosclerotic lesions in apoE-/- mice could be induced by a diet 
containing 1.25% cholesterol (wt/wt) and prevented by pravastatin. Our data indicates that pravastatin 
can prevent high-cholesterol diet-induced atherosclerosis in apoE-/- mice. The results are consistent 
with the current research in large clinical trials like CARE (Cholesterol and Recurrent Events) [17], 
WOSCOPS (West of Scotland Coronary Prevention Study) [18] and LIPID (Long-term Intervention 
with Pravastatin in Ischaemic Disease) [19]. Int. J. Mol. Sci. 2008, 9  
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Recently, HMG-CoA reductase inhibitors have been postulated to have pleiotropic effects, such as 
restoration of endothelial function, stabilization of atherosclerotic plaques, reduction of oxidative 
stress, anti-inflammatory actions, inhibition of thrombosis, and suppression of smooth muscle cell 
proliferation, improvement of insulin sensitivity and enhancement of vasculogenesis [12]. In our study, 
the results showed that the concentrations of TC and LDL-C in serum were significantly enhanced in 
atherosclerotic apoE-/- mice, however, the concentrations of TC and LDL-C were not significantly 
different in apoE-/- mice provided with pravastatin compared with atherosclerotic apoE-/- mice. Our 
results indicated that the effects of pravastatin on preventing atherosclerosis may not merely depend on 
decreasing serum lipid in apoE-/- mice. Previous research [20, 21] reported that pravastatin had no 
effect on plasma cholesterol concentration in apoE knockout mice and pravastatin treatment of 
atherosclerosis could not only be attributed to the reduction in plasma lipid levels, but also to its non-
cholesterol properties [13]. Consequently, this established animal model is beneficial to the research 
on non-cholesterol lowering actions of pravastatin preventing atherosclerosis. 
 
Figure 5. A. The expression of SOCS3 proteins extracted from the thoracoabdominal 
aortas and examined by western blotting. B. The expression of SOCS3 protein quantified 
by MutiGauge V 3.0 Imager and normalized to β-actin protein (n=6 per group). 
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Cytokines are well known to participate in the process of atherogenesis. Therefore, inhibition of 
cytokine agents has beneficial effects on the prevention of atherosclerosis. Consistent with our results, 
recent studies suggest that IL-6 plays an important role in the process of atherosclerosis [1], which is 
attributable to the fact that high cholesterol-diets induce the formation and overexpression of oxidized 
low-density lipoproteins, instrumental in triggering the early atherosclerotic events, and seems to 
uphold the inflammatory environment in atherosclerosis [22], including increases of IL-6 levels. Our 
data show that compared with atherosclerotic apoE-/- mice, IL-6 concentrations in serum and aortic 
atherosclerotic lesions of apoE-/- mice provided with pravastatin were significantly decreased, 
indicating that pravastatin may prevent atherosclerosis partially by attenuating IL-6 secretion. The 
results were consistent with the study showing that pravastatin therapy has been shown to provide 
significant reduction in the levels of inflammatory markers [15]. HMG-CoA reductase catalyzes the 
conversion of HMG-CoA to mevalonate [23], thereby the inhibitory effect of pravastatin on IL-6 
expression may be due to mevalonate starvation. However, the mechanisms of pravastatin attenuating 
IL-6 action during preventing aortic atherosclerosis are not yet fully understood. It is well known that 
identifying the signaling mechanisms that are common to many factors may eventually lead to the 
development of better therapeutic agents against atherosclerosis [24]. Since IL-6 can induce STAT3 
activation and phosphorylation, therefore, our results also suggested that pravastatin could decrease 
the upstream factor of STAT3 action in preventing aortic atherosclerosis.  
Interestingly, a number of atherosclerosis-related gene products were upregulated by STAT3, such 
as fibrinogen, angiotensinogen, monocyte chemotactic protein-1 (MCP-1), the LDL-receptor, and the 
adenosine triphosphate (ATP)-binding cassette transporter A1 [25]. Local activation of the IL-6-Jak-
STAT3 pathway may control many steps in the process of vascular remodeling, monocyte recruitment 
and neointimal formation [10]. Thus, STAT3 may possibly serve as a therapeutic target and has thus 
garnered a great deal of interest. Although recent research has reported that statins could reduce IL-6–
induced phosphorylation of STAT3 [26], it remains intangible whether STAT3 could play a key role in 
intervening with IL-6 action during the process of pravastatin prevention of aortic atherosclerosis. In 
our study, the expression of pSTAT3 in apoE-/- mice on a cholesterol-rich diet were obviously higher 
than that expression in control mice, while the overexpression of pSTAT3 was significantly down-
regulated in apoE-/- mice with cholesterol-rich diet supplemented with pravastatin. Our data indicated 
that pravastatin may down-regulate STAT3 activity and stream nucleus transcription molecules and 
gene expressions of atheroma-associated factors. Thus, our results suggested that pravastatin may 
prevent aortic atherosclerosis, in the part, by modulating STAT3 activity to attenuate IL-6 action. 
Since tamping the level of STAT3 activity would seem to represent a more judicious approach to 
block the development of atherosclerosis, the future use of the STAT3 specific inhibitors could be a 
new strategy to control atherosclerosis. It is known that cytokine response and the activation of STAT 
can be negatively regulated by the suppressor of cytokine signaling (SOCS) proteins [27]. Recent 
studies have revealed that SOCS3 determines the gene program activated by IL-6, and upregulated 
SOCS3 may help enhance a blockade of STAT3 signaling [28]. Based on these results, induction of 
SOCS is a therapeutic strategy for treating inflammatory diseases [29]. In our current study, that 
expression of SOCS3 was enhanced significantly in apoE-/- mice supplemented with pravastatin. Our 
data indicated that pravastatin enhanced SOCS3 expression in negative regulation of IL-6 action. Int. J. Mol. Sci. 2008, 9  
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Thus, our results suggested that pravastatin may prevent aortic atherosclerosis, in the part, by 
enhancing the inhibitory factors of STAT3 activity to decrease IL-6 action. 
In summary, besides advantageous lipid lowering, pravastatin appears to exert a direct beneficial 
effect on plaque stability. Pravastatin may down-regulate STAT3 and up-regulate SOCS3 as the 
inhibitory factor of STAT3 activities, thus preventing aortic atherosclerosis by attenuating IL-6 action. 
The present research reported that reduction of IL-6 in atherosclerosis by statins is observed not only 
in apoE-/- mice but also in human [30], therefore inhibition of STAT3 activity by pravastatin may also 
help prevent inflammation-mediated atherosclerosis in human. 
 
3. Experimental Section 
 
3.1. Animal experiments 
 
The apoE-/- mice can spontaneously develop atherosclerotic lesions on a standard chow diet and can 
develop advanced unstable atherosclerotic lesions in the brachiocephalic/innominate arteries that have 
many of the morphological features of advanced atherosclerotic lesions in humans, including 
intraplaque hemorrhage and rupture [20]. 
Male apoE-/- mice (8 weeks old, C57BL/6J background) were purchased from the Animal Center of 
Beijing Medical University (Beijing, P.R. China) and bred in the animal house of School of Medicine, 
Shanghai Jiao Tong University (Shanghai, P.R. China). Mice were maintained at a temperature 
22±2°C and relative humidity 55 ± 15%-controlled room with a 12-h light and dark cycle and fed with 
food and tap water ad libitum. All procedures were approved by the Animal Care and Use Committee 
of Shanghai Jiao Tong University. Pravastatin was kindly provided by Sankyo Co. Ltd. (Japan). 
Male C57BL/6J mice (8 weeks old) fed on a normal chow diet were provided with Phosphate 
Buffered Saline (PBS) by oral gavages (10 mL kg
-1 per day) as control group. Male apoE-/- mice fed 
on a diet containing 1.25% cholesterol and 0% cholate (wt/wt) were divided into pravastatin group 
provided with pravastatin (80 mg kg
-1, 10 mL kg
-1, per day) suspended in PBS by oral gavages and 
atherosclerosis group provided with PBS by oral gavages (10 mL kg
-1 per day) (n=12 per group). The 
pravastatin doses were chosen according to previous studies [31] and preliminary experiments in mice. 
  Eight weeks later, mice were euthanized after overnight fasting via anesthetic by intraperitoneal 
injection of sodium pentobarbital (1 mg kg
-1). Blood samples were taken before animals were killed 
and centrifuged at 1,000g for 20 min. Serum of each animal was collected. The excised aortic roots 
were examined for detailed histological analysis (n = 6 per group). The excised thoracoabdominal 
aortas (from the beginning of the aortic arch, just after the aortic roots, to the iliac bifurcation) were 
used for protein analysis (n = 6 per group). 
 
3.2. Assessing atherosclerosis lesion 
 
The aortic roots were embedded in paraffin. Sequential 5-μm sections were cut through the aortic 
root. We assessed atherosclerosis from six sections separated by 50 μm from one another. Paraffin 
sections were stained with hematoxylin and eosin. The first section displayed the entire 3-aortic valve 
leaflets. Images from sections were observed under microscope (Axioskop 20, ZEISS, Germany) and Int. J. Mol. Sci. 2008, 9  
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collected by camera (AxioCan HRC, ZEISS, Germany). The size of atherosclerotic lesion in each 
section was evaluated using Leica Qwin Image Processing and Analysis Software (Leica 
Microsystems, Wetzlar). In order to estimate the relative lesion size, we calculated the ratio of the 
lesion area compared with the total vessel wall area and expressed the ratio as a percentage. For each 
animal, every six sections were examined (n=6 per group). 
 
3.3. Analysis of serum lipid  
 
Concentrations of TC and LDL-C in serum were measured by Biochemistry Analyzer (ADVIA 
1650, Bayer, Tarrytown NY, USA) according to the manufacturer’s instructions, using individual 
serum samples from six mice in each group. 
 
3.4. Western Blotting analysis 
 
The thoracoabdominal aortas extraction, SDS-PAGE and Western Blotting analysis were performed 
as previously described [32]. Briefly, the thoracoabdominal aortas tissue extracted were prepared by 
homogenation in lysis buffer (50 mM Tris, pH 7.5, 150 mM sodium chloride, 1 mM 
phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 1% Nonidet P-40, 50 mM sodium 
fluoride, 10 μg/mL proteinase inhibitors mixture, 10% glycerol) at 4°C, followed by centrifugation at 
16 000 rpm at 4°C for 10 min. After quantification of protein concentrations, the supernatants were 
mixed in Laemmli loading buffer, boiled for 4 min, and then subjected to Western blotting analysis. 
PVDF were blotted against primary antibodies at 4°C for 16 h, washed with 0.05% (vol/vol) Tween 20 
in TBS (pH 7.4), and incubated with horseradish peroxidase-conjugated secondary antibodies for 45 
min. Protein bands were visualized by the enhanced chemiluminescence reaction method (Applygen 
Technologies Inc., Beijing) (n=6 per group). Primary antibodies included anti-phospho-STAT3 
(Tyr705), anti-SOCS3, and anti-β-actin antibody which were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA).  
 
3.5. Analysis of ELISA 
 
Concentrations of IL-6 in thoracoabdominal aorta and serum were measured by enzyme linked 
immunosorbent assay (ELISA). Concentrations of IL-6 were measured by commercially available 
Mouse IL-6 ELISA Ready-SET-Go! (eBioscience co, San Diego, USA), according to the 
manufacturer’s instructions (eBioscience co, Diego, USA) (n=6 per group). Concentrations of IL-6 
were quantified by Universal Microplate Reader (ELx800, BioTek Instruments Inc, Winooski, 
Vermont, USA). 
 
3.6. Statistical analysis 
 
  Data are expressed as means±SD. To determine whether variations amongst different groups are 
statistically significant, data were analyzed by one-way analysis of variance ANOVA followed by 
unpaired Student’s t-test. The results obtained were reproducible between experiments. Each data Int. J. Mol. Sci. 2008, 9  
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point represents n=6. Individual statistical comparisons of paired data were evaluated with P <0.05 
representing significance. 
 
4. Conclusions 
 
Our findings furnish a new mechanism through which pravastatin can prevent aortic atherosclerosis 
via attenuating IL-6 action by the modulation of STAT3 activity in apoE-/- mice. Our findings provide 
a new therapeutic approach for insight into clinical benefits of pravastatin and further insights into the 
intervening approaches of atherosclerosis. Our research may initiate rational and new therapeutic 
concepts for pravastatin in the future. 
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